BioNTech SE (BNTX) Free Cash Flow Yield: 5.77%
Is BioNTech SE’s free cash flow yield high or low?
BioNTech SE's free cash flow yield of 5.77% is 63% below its 5-year average of 15.40%, near the low end of its 5-year range (1.01%–43.86%).
The free cash flow yield for BioNTech SE (BNTX) is 5.77% as of Tuesday, June 9, 2026. It is above its 12-month average by 14.45% (5.04%).
BNTX Free Cash Flow Yield Chart
BNTX Average Free Cash Flow Yield Chart
BNTX Current vs Average Free Cash Flow Yield Chart
BNTX Free Cash Flow Yield Metrics
FREE CASH FLOW YIELD
5.77%
FREE CASH FLOW YIELD AVG TTM
5.04%
FREE CASH FLOW YIELD AVG 3Y
12.98%
FREE CASH FLOW YIELD AVG 5Y
15.40%
FREE CASH FLOW YIELD AVG 10Y
15.40%
FREE CASH FLOW YIELD AVG 15Y
15.40%
FREE CASH FLOW YIELD AVG 20Y
15.40%
CURRENT VS TTM AVG
+14.45%
CURRENT VS 3Y AVG
-55.54%
CURRENT VS 5Y AVG
-62.53%
CURRENT VS 10Y AVG
-62.53%
CURRENT VS 15Y AVG
-62.53%
CURRENT VS 20Y AVG
-62.53%
BNTX Competitors' Free Cash Flow Yield
| NAME | MARKET CAP | FREE CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BioNTech SE (BNTX) | — | 5.77% | 5.04% | 12.98% | 15.40% |
| Mettler-Toledo International Inc. (MTD) | $23.50B | 3.37% | 3.21% | 3.24% | 2.88% |
| Waters Corporation (WAT) | $24.19B | 0.87% | 2.84% | 2.68% | 2.70% |
| Moderna, Inc. (MRNA) | $18.94B | 3.17% | 4.54% | 3.17% | 6.54% |
| Hologic, Inc. (HOLX) | $16.97B | 5.82% | 6.30% | 5.70% | 7.89% |
| Veeva Systems Inc. (VEEV) | $27.37B | 1.86% | 3.52% | 3.07% | 2.74% |
| Biogen Inc. (BIIB) | $29.39B | 8.88% | 9.21% | 6.93% | 6.70% |
| DexCom, Inc. (DXCM) | $30.17B | 4.64% | 3.31% | 2.07% | 1.40% |
| Align Technology, Inc. (ALGN) | $12.76B | 5.38% | 5.41% | 3.76% | 3.04% |
| IQVIA Holdings Inc. (IQV) | $31.09B | 8.45% | 7.33% | 5.48% | 5.07% |
Yield Comparison
FCF Yield
5.77%
Earnings Yield
0.50%
Dividend Yield
2.44%
Formula: FCF Yield = (Free Cash Flow / Market Cap) × 100
How FCF Yield is used:
- Shows free cash flow after capital expenditures relative to market cap
- Can be compared with earnings yield and dividend yield
- Can be compared with the company's historical range
- Can be compared with peers that report positive free cash flow
FCF vs earnings: Differences between FCF yield and earnings yield can reflect capital expenditures, working capital changes, and other non-cash accounting items.
BioNTech SE Free Cash Flow Yield Formula & Definition
FCF Yield measures free cash flow relative to market capitalization. It compares cash generation after capital expenditures with the equity value of the company.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
BioNTech SE Free Cash Flow Yield FAQ
- What is the free cash flow yield for BioNTech SE (BNTX)?
- The free cash flow yield for BNTX stock is 5.77%.
- Is BioNTech SE's free cash flow yield high or low?
- BioNTech SE's free cash flow yield of 5.77% is 63% below its 5-year average of 15.40%, near the low end of its 5-year range (1.01%–43.86%).
- What is the TTM average free cash flow yield for BioNTech SE (BNTX)?
- The TTM average free cash flow yield for BNTX stock is 5.04%.
- What is the 3Y average free cash flow yield for BioNTech SE (BNTX)?
- The 3Y average free cash flow yield for BNTX stock is 12.98%.
- What is the 5Y average free cash flow yield for BioNTech SE (BNTX)?
- The 5Y average free cash flow yield for BNTX stock is 15.40%.
- What is the 10Y average free cash flow yield for BioNTech SE (BNTX)?
- The 10Y average free cash flow yield for BNTX stock is 15.40%.
- What is the 15Y average free cash flow yield for BioNTech SE (BNTX)?
- The 15Y average free cash flow yield for BNTX stock is 15.40%.
- What is the 20Y average free cash flow yield for BioNTech SE (BNTX)?
- The 20Y average free cash flow yield for BNTX stock is 15.40%.
BioNTech SE Free Cash Flow Yield History
| DATE | FREE CASH FLOW YIELD |
|---|---|
| 2026-06-09 | 5.77% |
| 2026-06-08 | 5.84% |
| 2026-06-05 | 5.67% |
| 2026-06-04 | 5.57% |
| 2026-06-03 | 5.65% |
| 2026-06-02 | 5.60% |
| 2026-06-01 | 5.45% |
| 2026-05-29 | 5.21% |
| 2026-05-28 | 5.34% |
| 2026-05-27 | 5.37% |
| 2026-05-26 | 5.41% |
| 2026-05-22 | 5.42% |
| 2026-05-21 | 5.49% |
| 2026-05-20 | 5.53% |
| 2026-05-19 | 5.69% |
| 2026-05-18 | 5.62% |
| 2026-05-15 | 5.58% |
| 2026-05-14 | 5.43% |
| 2026-05-13 | 5.42% |
| 2026-05-12 | 5.33% |
| 2026-05-11 | 5.35% |
| 2026-05-08 | 5.31% |
| 2026-05-07 | 5.37% |
| 2026-05-06 | 5.24% |
| 2026-05-05 | 5.23% |
| 2026-05-04 | 1.14% |
| 2026-05-01 | 1.16% |
| 2026-04-30 | 1.09% |
| 2026-04-29 | 1.11% |
| 2026-04-28 | 1.11% |
| 2026-04-27 | 1.11% |
| 2026-04-24 | 1.07% |
| 2026-04-23 | 1.07% |
| 2026-04-22 | 1.04% |
| 2026-04-21 | 1.01% |
| 2026-04-20 | 1.07% |
| 2026-04-17 | 1.10% |
| 2026-04-16 | 1.11% |
| 2026-04-15 | 1.13% |
| 2026-04-14 | 1.15% |
| 2026-04-13 | 1.17% |
| 2026-04-10 | 1.18% |
| 2026-04-09 | 1.23% |
| 2026-04-08 | 1.23% |
| 2026-04-07 | 1.26% |
| 2026-04-06 | 1.24% |
| 2026-04-02 | 1.24% |
| 2026-04-01 | 1.26% |
| 2026-03-31 | 1.27% |
| 2026-03-30 | 1.32% |
| 2026-03-27 | 1.32% |
| 2026-03-26 | 1.29% |
| 2026-03-25 | 1.27% |
| 2026-03-24 | 1.30% |
| 2026-03-23 | 1.28% |
| 2026-03-20 | 1.26% |
| 2026-03-19 | 1.26% |
| 2026-03-18 | 1.25% |
| 2026-03-17 | 1.19% |
| 2026-03-16 | 1.25% |
| 2026-03-13 | 1.24% |
| 2026-03-12 | 1.25% |
| 2026-03-11 | 1.24% |
| 2026-03-10 | 1.35% |
| 2026-03-09 | 5.92% |
| 2026-03-06 | 5.96% |
| 2026-03-05 | 5.93% |
| 2026-03-04 | 5.82% |
| 2026-03-03 | 6.00% |
| 2026-03-02 | 5.62% |
| 2026-02-27 | 5.49% |
| 2026-02-26 | 5.56% |
| 2026-02-25 | 5.50% |
| 2026-02-24 | 5.45% |
| 2026-02-23 | 5.50% |
| 2026-02-20 | 5.49% |
| 2026-02-19 | 5.47% |
| 2026-02-18 | 5.60% |
| 2026-02-17 | 5.65% |
| 2026-02-13 | 5.71% |
| 2026-02-12 | 5.72% |
| 2026-02-11 | 5.53% |
| 2026-02-10 | 5.55% |
| 2026-02-09 | 5.48% |
| 2026-02-06 | 5.67% |
| 2026-02-05 | 5.73% |
| 2026-02-04 | 5.56% |
| 2026-02-03 | 5.58% |
| 2026-02-02 | 5.55% |
| 2026-01-30 | 5.31% |
| 2026-01-29 | 5.18% |
| 2026-01-28 | 5.20% |
| 2026-01-27 | 5.07% |
| 2026-01-26 | 5.12% |
| 2026-01-23 | 5.21% |
| 2026-01-22 | 5.10% |
| 2026-01-21 | 5.12% |
| 2026-01-20 | 5.73% |
| 2026-01-16 | 5.55% |
| 2026-01-15 | 5.70% |
| 2026-01-14 | 5.54% |
| 2026-01-13 | 5.64% |
| 2026-01-12 | 5.92% |
| 2026-01-09 | 6.05% |
| 2026-01-08 | 6.12% |
| 2026-01-07 | 6.04% |
| 2026-01-06 | 6.16% |
| 2026-01-05 | 6.24% |
| 2026-01-02 | 6.25% |
| 2025-12-31 | 6.35% |
| 2025-12-30 | 6.35% |
| 2025-12-29 | 6.35% |
| 2025-12-26 | 6.39% |
| 2025-12-24 | 6.36% |
| 2025-12-23 | 6.42% |
| 2025-12-22 | 6.56% |
| 2025-12-19 | 6.54% |
| 2025-12-18 | 6.61% |
| 2025-12-17 | 6.60% |
| 2025-12-16 | 6.55% |
| 2025-12-15 | 6.44% |
| 2025-12-12 | 6.38% |
| 2025-12-11 | 6.30% |
| 2025-12-10 | 6.31% |
| 2025-12-09 | 6.31% |
| 2025-12-08 | 6.22% |
| 2025-12-05 | 6.28% |
| 2025-12-04 | 6.30% |
| 2025-12-03 | 6.25% |
| 2025-12-02 | 6.29% |
| 2025-12-01 | 6.21% |
| 2025-11-28 | 5.86% |
| 2025-11-26 | 5.89% |
| 2025-11-25 | 6.06% |
| 2025-11-24 | 6.26% |
| 2025-11-21 | 6.33% |
| 2025-11-20 | 6.23% |
| 2025-11-19 | 5.96% |
| 2025-11-18 | 5.90% |
| 2025-11-17 | 5.89% |
| 2025-11-14 | 5.87% |
| 2025-11-13 | 5.82% |
| 2025-11-12 | 5.41% |
| 2025-11-11 | 5.56% |
| 2025-11-10 | 5.75% |
| 2025-11-07 | 5.86% |
| 2025-11-06 | 5.85% |
| 2025-11-05 | 5.84% |
| 2025-11-04 | 5.77% |
| 2025-11-03 | 5.81% |
| 2025-10-31 | 5.82% |
| 2025-10-30 | 5.78% |
| 2025-10-29 | 5.85% |
| 2025-10-28 | 5.76% |
| 2025-10-27 | 5.70% |
| 2025-10-24 | 5.72% |
| 2025-10-23 | 5.77% |
| 2025-10-22 | 5.69% |
| 2025-10-21 | 5.66% |
| 2025-10-20 | 5.60% |
| 2025-10-17 | 5.75% |
| 2025-10-16 | 5.75% |
| 2025-10-15 | 5.79% |
| 2025-10-14 | 5.89% |
| 2025-10-13 | 5.91% |
| 2025-10-10 | 5.92% |
| 2025-10-09 | 5.79% |
| 2025-10-08 | 5.69% |
| 2025-10-07 | 5.70% |
| 2025-10-06 | 5.75% |
| 2025-10-03 | 5.73% |
| 2025-10-02 | 5.78% |
| 2025-10-01 | 5.91% |
| 2025-09-30 | 6.13% |
| 2025-09-29 | 6.16% |
| 2025-09-26 | 6.17% |
| 2025-09-25 | 6.17% |
| 2025-09-24 | 6.06% |
| 2025-09-23 | 6.15% |
| 2025-09-22 | 6.12% |
| 2025-09-19 | 6.28% |
| 2025-09-18 | 6.28% |
| 2025-09-17 | 6.16% |
| 2025-09-16 | 6.09% |
| 2025-09-15 | 6.18% |
| 2025-09-12 | 6.25% |
| 2025-09-11 | 5.79% |
| 2025-09-10 | 5.98% |
| 2025-09-09 | 5.92% |
| 2025-09-08 | 5.89% |
| 2025-09-05 | 5.38% |
| 2025-09-04 | 5.84% |
| 2025-09-03 | 6.02% |
| 2025-09-02 | 6.01% |
| 2025-08-29 | 6.05% |
| 2025-08-28 | 5.93% |
| 2025-08-27 | 5.87% |
| 2025-08-26 | 5.77% |
| 2025-08-25 | 5.75% |
| 2025-08-22 | 5.45% |
| 2025-08-21 | 5.46% |
| 2025-08-20 | 5.43% |
| 2025-08-19 | 5.43% |
| 2025-08-18 | 5.37% |
| 2025-08-15 | 5.32% |
| 2025-08-14 | 5.36% |
| 2025-08-13 | 5.36% |
| 2025-08-12 | 5.45% |
| 2025-08-11 | 5.53% |
| 2025-08-08 | 5.41% |
| 2025-08-07 | 5.43% |
| 2025-08-06 | 5.43% |
| 2025-08-05 | 5.44% |
| 2025-08-04 | 5.49% |
| 2025-08-01 | 5.63% |
| 2025-07-31 | 5.62% |
| 2025-07-30 | 5.49% |
| 2025-07-29 | 5.42% |
| 2025-07-28 | 5.36% |
| 2025-07-25 | 5.24% |
| 2025-07-24 | 5.28% |
| 2025-07-23 | 5.27% |
| 2025-07-22 | 5.43% |
| 2025-07-21 | 5.55% |
| 2025-07-18 | 5.49% |
| 2025-07-17 | 5.44% |
| 2025-07-16 | 5.37% |
| 2025-07-15 | 5.46% |
| 2025-07-14 | 5.45% |
| 2025-07-11 | 5.36% |
| 2025-07-10 | 5.31% |
| 2025-07-09 | 5.41% |
| 2025-07-08 | 5.41% |
| 2025-07-07 | 5.49% |
| 2025-07-03 | 5.49% |
| 2025-07-02 | 5.58% |
| 2025-07-01 | 5.62% |
| 2025-06-30 | 5.68% |
| 2025-06-27 | 5.67% |
| 2025-06-26 | 5.69% |
| 2025-06-25 | 5.77% |
| 2025-06-24 | 5.75% |
| 2025-06-23 | 5.87% |
| 2025-06-20 | 5.68% |
| 2025-06-18 | 5.79% |
| 2025-06-17 | 5.76% |
| 2025-06-16 | 5.69% |
| 2025-06-13 | 5.67% |
| 2025-06-12 | 5.76% |
| 2025-06-11 | 5.73% |
| 2025-06-10 | 5.66% |
| 2025-06-09 | 5.55% |
| 2025-06-06 | 5.57% |
| 2025-06-05 | 5.49% |
| 2025-06-04 | 5.44% |
| 2025-06-03 | 5.23% |
| 2025-06-02 | 5.34% |
| 2025-05-30 | 6.31% |
| 2025-05-29 | 6.03% |
| 2025-05-28 | 6.20% |
Showing the most recent 260 of 1,177 data points. The chart above shows the full history.
About BioNTech SE
BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer. BNT113 is undergoing Phase 2 investigation for HPV-positive head and neck cancers. BNT114 is in Phase 1 for triple-negative breast cancer. BNT115 is also in Phase 1, targeting ovarian cancer. BNT116 is a preclinical candidate for non-small cell lung cancer. The company also pioneers personalized therapies that target neoantigens, such as Autogene cevumeran (BNT122), which is in Phase 2 for first-line melanoma and Phase 1a/1b for a range of solid tumors. Furthermore, its pipeline includes an mRNA-based intratumoral immunotherapy, SAR441000, currently in Phase 1 for solid tumors, as well as BNT141 and BNT142, also in Phase 1 for multiple solid tumors. BioNTech's portfolio extends to RiboCytokine therapies (BNT151, BNT152, and BNT153) aimed at solid tumors, and cutting-edge chimeric antigen receptor T-cell (CAR T-cell) immunotherapies like BNT211 for various solid tumors and BNT221 for other types of cancer. Immune checkpoint modulators, specifically GEN1046 and GEN1042, are also under Phase 1/2 clinical investigation for solid tumors. Beyond these, the firm is developing BNT321, an IgG1 monoclonal antibody in Phase 2 for pancreatic cancer, and BNT411, a small molecule immunomodulator candidate for solid tumors. Its broader scope encompasses preventative vaccines for illnesses like COVID-19 and Influenza, additional immunotherapies for infectious diseases, and protein replacement therapies designed for rare conditions. To advance its extensive pipeline, BioNTech has forged strategic partnerships with major pharmaceutical and biotechnology firms, including Genentech, Sanofi S.A., Genmab A/S, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Regeneron Pharmaceuticals, Inc. Established in 2008, BioNTech SE maintains its principal operations in Mainz, Germany.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Ugur Sahin